See the published version of this preprint at Trials.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Study protocol
Jian Wang
State Key Laboratory of respiratory disease
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1278-256X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction Tetramethylpyrazine (TMP), one of the active ingredients from the traditional Chinese herbal medicine Rhizoma Chuanxiong (Chuanxiong), has been clinically used for the prevention and treatment on cardiovascular diseases. The benefits of TMP are largely attributed to its anti-oxidize and vasodilative activities. However, the efficacy of TMP in the treatment of pulmonary hypertension(PH) is unknown, in this study, we hypothesized that TMP treatment has a therapeutic effect on PH patients.
Keywords
pulmonary hypertension, tetramethylpyrazine, randomized controlled study
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Trials.
Version 2
Posted 15 Oct, 2019
No community comments so far
Editorial decision: Accept
On 29 Sep, 2019
Review #1 received
Received 23 Sep, 2019
Reviewer #1 agreed
On 17 Sep, 2019
Editor assigned
On 16 Sep, 2019
Reviewers invited
Invitations sent on 16 Sep, 2019
Submission checks complete
On 15 Sep, 2019
No comments provided
Editorial decision: Major revision
On 17 Aug, 2019
Review #1 received
Received 11 Aug, 2019
Review #2 received
Received 11 Aug, 2019
Reviewers invited
Invitations sent on 25 Jul, 2019
Reviewer #1 agreed
On 25 Jul, 2019
Reviewer #2 agreed
On 25 Jul, 2019
Editor assigned
On 17 Jun, 2019
Submission checks complete
On 30 Apr, 2019
First submitted
On 09 Apr, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Interdisciplinary Medicine
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Trials.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Study protocol
Jian Wang
State Key Laboratory of respiratory disease
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1278-256X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Trials.
Version 2
Posted 15 Oct, 2019
No community comments so far
Editorial decision: Accept
On 29 Sep, 2019
Review #1 received
Received 23 Sep, 2019
Reviewer #1 agreed
On 17 Sep, 2019
Editor assigned
On 16 Sep, 2019
Reviewers invited
Invitations sent on 16 Sep, 2019
Submission checks complete
On 15 Sep, 2019
No comments provided
Editorial decision: Major revision
On 17 Aug, 2019
Review #1 received
Received 11 Aug, 2019
Review #2 received
Received 11 Aug, 2019
Reviewers invited
Invitations sent on 25 Jul, 2019
Reviewer #1 agreed
On 25 Jul, 2019
Reviewer #2 agreed
On 25 Jul, 2019
Editor assigned
On 17 Jun, 2019
Submission checks complete
On 30 Apr, 2019
First submitted
On 09 Apr, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Interdisciplinary Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Trials.
Introduction Tetramethylpyrazine (TMP), one of the active ingredients from the traditional Chinese herbal medicine Rhizoma Chuanxiong (Chuanxiong), has been clinically used for the prevention and treatment on cardiovascular diseases. The benefits of TMP are largely attributed to its anti-oxidize and vasodilative activities. However, the efficacy of TMP in the treatment of pulmonary hypertension(PH) is unknown, in this study, we hypothesized that TMP treatment has a therapeutic effect on PH patients.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...